GSK-4532990

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameGSK-4532990
Drug Alias NameARO-HSDGSK4532990GSK-4532990VSA-006VSA006
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of Action17-beta-hydroxysteroid dehydrogenase 13 Expression InhibitorsRNA interference
Targets17-beta-hydroxysteroid dehydrogenase 13
Therapy Area/IndicationsLiver Diseases, AlcoholicMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaPanama +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesArrowhead Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesVisirna Biotechnology (Shanghai) Co LtdGlaxosmithkline PlcArrowhead Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsLiver Diseases, AlcoholicMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A